The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Subscribe To Our Newsletter & Stay Updated
